14.88
-0.68(-4.37%)
Currency In USD
| Previous Close | 15.56 |
| Open | 15.53 |
| Day High | 15.65 |
| Day Low | 14.85 |
| 52-Week High | 72.37 |
| 52-Week Low | 9.12 |
| Volume | 818,107 |
| Average Volume | 589,267 |
| Market Cap | 604.35M |
| PE | 46.5 |
| EPS | 0.32 |
| Moving Average 50 Days | 15.38 |
| Moving Average 200 Days | 13.46 |
| Change | -0.68 |
If you invested $1000 in Keros Therapeutics, Inc. (KROS) since IPO date, it would be worth $741.04 as of October 24, 2025 at a share price of $14.88. Whereas If you bought $1000 worth of Keros Therapeutics, Inc. (KROS) shares 3 years ago, it would be worth $340.58 as of October 24, 2025 at a share price of $14.88.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares
GlobeNewswire Inc.
Oct 20, 2025 10:00 AM GMT
LEXINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of
Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital
GlobeNewswire Inc.
Oct 15, 2025 10:30 AM GMT
Agrees to Repurchase of All Shares Held By ADAR1 Capital Management and Pontifax Venture Capital Plans to Commence Tender Offer to Repurchase up to $194 Million of Additional Shares LEXINGTON, Mass., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Keros Therapeu
Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting
GlobeNewswire Inc.
Sep 08, 2025 12:00 PM GMT
LEXINGTON, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with d